The data on GLP-1s and diabetes prevention is among the most compelling in recent clinical research. Here's what it means for the 96 million Americans with prediabetes.
Prediabetes is diagnosed in approximately 96 million American adults—nearly 1 in 3. Of those, about 80% don't know they have it. Without intervention, roughly 25% of people with prediabetes will develop Type 2 diabetes within 3–5 years, and nearly 70% will develop it over their lifetime.
GLP-1 medications like semaglutide and tirzepatide, while not approved specifically for prediabetes, are showing remarkable results in preventing the progression from prediabetes to Type 2 diabetes. The numbers from clinical trials are striking enough to change how the field is thinking about early intervention.
Prediabetes is a condition of impaired blood sugar regulation—blood glucose levels that are elevated above normal but haven't yet crossed the diagnostic threshold for Type 2 diabetes. It's diagnosed by any of the following:
| Test | Normal | Prediabetes | Diabetes |
|---|---|---|---|
| Fasting blood glucose | <100 mg/dL | 100–125 mg/dL | ≥126 mg/dL |
| A1C | <5.7% | 5.7–6.4% | ≥6.5% |
| 2-hour OGTT | <140 mg/dL | 140–199 mg/dL | ≥200 mg/dL |
Prediabetes reflects underlying insulin resistance—cells aren't responding effectively to insulin, and the pancreas is compensating by producing more. Over time, the pancreatic beta cells can become exhausted, insulin production falls, and blood sugar rises into the diabetic range.
GLP-1 medications address prediabetes through multiple mechanisms simultaneously:
Insulin resistance is strongly linked to excess adiposity—particularly visceral fat (fat around the organs). GLP-1 medications produce significant weight loss (10–20%+ of body weight in trials), which directly reduces visceral fat and improves insulin sensitivity. This is likely the primary mechanism of diabetes prevention in people with prediabetes and obesity.
GLP-1 agonists also have direct effects on the pancreas. They stimulate insulin secretion in response to food (glucose-dependent, so they don't cause hypoglycemia on their own) and suppress glucagon release (which prevents inappropriate glucose release from the liver). These effects help maintain more stable blood sugar levels and may reduce the metabolic stress on pancreatic beta cells.
GLP-1 medications reduce hepatic fat (liver fat), which is independently associated with insulin resistance and prediabetes. Reducing liver fat improves insulin sensitivity in the liver, where a large portion of glucose regulation occurs.
The STEP-1 trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without Type 2 diabetes. A significant proportion had prediabetes at baseline.
Key findings for the prediabetes subgroup:
That 84% normoglycemia reversal rate is a striking number. It suggests that for many people with prediabetes and obesity, pharmacologically supported weight loss can substantially reverse the metabolic dysfunction driving the condition.
The SURMOUNT-1 trial tested tirzepatide (Mounjaro/Zepbound) in adults with obesity without diabetes. Results in the prediabetes subgroup were even more striking:
This near-complete normalization of blood sugar in people with prediabetes—95%—is extraordinary. For comparison, intensive lifestyle intervention in the Diabetes Prevention Program (DPP) reduced T2D progression by about 58%; metformin reduced it by about 31%. Tirzepatide's effects in these trial subgroups dwarf both.
The SELECT trial demonstrated cardiovascular risk reduction with semaglutide in non-diabetic patients with obesity and established cardiovascular disease. While not a prediabetes-specific trial, about 38% of participants had prediabetes at baseline. The cardiovascular risk reduction was observed across this subgroup as well.
This is where the evidence and the practical reality diverge somewhat. GLP-1 medications are not FDA-approved for prediabetes as a primary indication. The approved weight management indications are:
Prediabetes qualifies as a weight-related comorbidity in Wegovy's and Zepbound's prescribing information. This means if you have prediabetes and BMI ≥27, you likely qualify for a Wegovy or Zepbound prescription.
Use our Eligibility Checker to see how your BMI, A1C, and other health factors map to clinical qualification criteria.
Insurance coverage for weight management GLP-1s in patients with prediabetes is inconsistent. Some plans cover Wegovy with prediabetes documented as the qualifying comorbidity; others require more traditional comorbidities like hypertension or dyslipidemia. Your prescriber's documentation of prediabetes severity (A1C, fasting glucose trend, risk trajectory) can strengthen a prior authorization submission.
Medicare does not cover Wegovy or Zepbound for weight management (with the narrow sleep apnea exception for Zepbound). If you're on Medicare with prediabetes, you're currently in a coverage gap—GLP-1 medications for weight management and diabetes prevention are not covered, even though the diabetes itself (once it progresses) would be covered by Part D.
The most powerful intervention for prediabetes remains the same as it has been for decades: weight loss and exercise. The Diabetes Prevention Program showed that losing 5–7% of body weight and getting 150 minutes of moderate exercise per week reduces T2D progression by 58%.
GLP-1 medications don't replace that framework—they make achieving it dramatically more accessible. For many people with prediabetes who have struggled to lose and maintain weight through lifestyle changes alone, pharmacological support removes the biggest barrier.
The clinical picture that's emerging: GLP-1 medications, by producing 10–20% weight loss, are achieving weight loss percentages that far exceed the 5–7% associated with DPP-style interventions—and the blood sugar normalization rates in trials reflect this more potent intervention.
If you have prediabetes and are overweight or obese, asking your doctor directly about GLP-1 medications is appropriate. Key points to raise:
The window between prediabetes and Type 2 diabetes is one of the highest-leverage intervention points in metabolic medicine. The data suggests GLP-1 medications may be the most effective pharmacological tool we have for this transition. Whether they're accessible for you depends on your BMI, insurance, and your provider's familiarity with the evidence—but the case for asking is strong.
For Ozempic specifically: yes, it's FDA-approved for Type 2 diabetes. For weight management GLP-1s (Wegovy, Zepbound), you don't need a diabetes diagnosis—you need BMI ≥30, or BMI ≥27 with a weight-related comorbidity. Prediabetes counts as a qualifying comorbidity for Wegovy eligibility at BMI ≥27.
Yes, for many people. Losing 5–7% of body weight and achieving 150 minutes/week of moderate exercise reduces T2D progression by ~58% (Diabetes Prevention Program data). Normoglycemia reversion is achievable through lifestyle changes. GLP-1 medications produce much larger weight losses and higher reversion rates, but lifestyle intervention remains the first-line recommendation and is effective for many people.
There's no specific A1C cutoff for GLP-1 consideration in people with prediabetes. The eligibility is based on weight criteria (BMI ≥27 with prediabetes as comorbidity, or BMI ≥30). However, a rising A1C trend—especially toward the upper end of prediabetes (6.0–6.4%)—makes a stronger clinical case for pharmacological intervention given the proximity to the diabetes threshold.
See if your BMI, A1C, and health conditions qualify you for a GLP-1 prescription under current FDA-approved criteria.
Check Eligibility →Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Prediabetes management should be individualized. Clinical trial results represent population averages and may not predict your individual outcome. Consult a licensed healthcare provider—ideally your primary care physician or an endocrinologist—before starting any medication for prediabetes or weight management.
Compare Providers
These providers offer online consultations, licensed prescribers, and medication shipped to your door.
GLP-1 specialist. Fast evaluation, compounded semaglutide & tirzepatide, competitive pricing.
Get Started →High patient satisfaction. Compounded semaglutide at lower cost. No in-person visit required.
Get Started →Connects patients with licensed GLP-1 prescribers. Multiple medication options, ongoing support.
Get Started →Compare all GLP-1 providers → • Sponsored links. Medical evaluation required. Results vary. See full provider comparison.